Transcriptome analysis profile to understand mechanisms activated by FDA molecules that overcome the ATP7B mediated resistance to cisplatin in ovarian cancer IGROV-CP20 cells.

To understand whether treatments with FDA drugs Trelmisartan, Tranilast or Amphotericin B were able to downregulate pathways important to overcome resistance to cisplatin in ovarian cancer cells IGROV-0CP20 we cemployed Quant-seq Analysis.Transcriptome of the of IGROV-CP20 cells treated with cisplatin and each of the three FDA molecules were compared with untreated cells. Total RNA was extracted from IGROV-CP20 cells treated with cisplatin (T) or a combination of cisplatin and each of the following drugs: Telmisartan, Tranilast and Amphotericin B; RNA extracted from untreated cells was used as control.